国家"团购"药品再发力。 最新一批国家组织药品集中带量采购27日在上海开标，55种药品全部采购成功，272家企业的453个产品 获得拟中选资格。至此，国家组织集采已覆盖490种药品，药品清单持续扩容。 科学遴选，满足临床刚需。 此次集采共有445个企业的794个产品参与，部分品种的投标企业数量较多，竞争非常激烈，同一个品种 竞争企业数量最多的达到40家以上。 业内人士认为，这一方面反映出我国医药产业拥有充足的生产供应能力，另一方面也提示应该引导企业 科学立项，避免集中扎堆生产同一药品。 郑颐介绍，此次集采设置了两轮"复活机会"，总体上是弱淘汰机制，与所谓"最低价中选"的刻板印象不 同，实际上每个集采药品大概有60%以上的投标企业中选。 "相较此前，这次集采更加注重质量保障、供应链稳定，将稳临床、保质量、防围标、反内卷落在了实 处。"上海市卫生和健康发展研究中心主任金春林介绍。 "很多品种都是上市多年、临床使用成熟的老药，而且规格比较多，为公众提供更多用药选择。"国家组 织药品联合采购办公室主任郑颐介绍。 具体来看，新一批集采药品的"民生属性"凸显：既有地氯雷他定、倍他米松等抗过敏哮喘药物，也有二 甲双胍恩格列 ...

Core Viewpoint - The company Aorite (605116.SH) announced a share reduction plan due to the funding needs of some partners, with a maximum reduction of 2,176,600 shares, accounting for 0.54% of the total share capital [1] Group 1: Shareholding Structure - As of the announcement date, the total number of shares of the company is 406,195,234, with Tian Tai Bo Rong and its concerted parties holding a total of 170,096,400 shares, representing 41.88% of the total share capital [1] - Tian Tai Bo Rong holds 9,907,200 shares, accounting for 2.44% of the total share capital, while Zhejiang Tong Ben holds 153,583,200 shares, representing 37.81% [1] Group 2: Fundraising and Projects - Aorite was listed on the Shanghai Stock Exchange on September 21, 2020, with a total fundraising amount of 34,317.00 million yuan, and a net amount of 28,404.13 million yuan after deducting issuance costs [2] - The funds raised are intended for projects including the technical transformation of production lines for various pharmaceutical products and the construction of a pilot experimental center [2][3] - The total investment for the projects is 46,110.00 million yuan, with specific allocations for each project detailed in the report [3] Group 3: Convertible Bonds - Aorite plans to issue convertible bonds with a total face value of 81,212.00 million yuan, raising approximately 800,471,428.30 yuan after deducting issuance costs [4] - The issuance is conducted by the lead underwriter Guotai Junan Securities Co., Ltd., and the funds have been verified and deposited into the company's fundraising supervision account [4]

Group 1 - The company, Saito Bio (300583), produces key starting materials for common COPD treatments, including dehydroepiandrosterone, betamethasone, and indacaterol maleate [1] - The company does not currently produce formulations specifically for COPD [1]

Group 1 - The company produces key starting materials for common COPD (Chronic Obstructive Pulmonary Disease) treatments, including dehydroepiandrosterone, betamethasone, and indacaterol maleate [1] - The company does not currently produce formulations specifically for COPD [1]